CytoMed Therapeutics (GDTC) Receivables (2021 - 2025)

CytoMed Therapeutics has disclosed Receivables across 5 years of filings, most recently posting $1.6 million for Q4 2025.

• In Q4 2025, Receivables rose 37.81% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.6 million (up 37.81% YoY), while the FY2025 annual figure was $1.6 million, up 87.74% from the prior year.
• Receivables came in at $1.6 million for Q4 2025 at CytoMed Therapeutics, up from $1.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.6 million in Q4 2025 to a low of $581771.7 in Q4 2021.
• Average Receivables over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
• Year-over-year, Receivables soared 41.67% in 2023 and increased 14.15% in 2024.
• Over 5 years, Receivables stood at $581771.7 in 2021, then grew by 22.28% to $711402.2 in 2022, then surged by 41.67% to $1.0 million in 2023, then advanced by 14.15% to $1.2 million in 2024, then jumped by 37.81% to $1.6 million in 2025.
• Per Business Quant data, the three most recent Receivables figures were $1.6 million in Q4 2025, $1.3 million in Q2 2025, and $1.2 million in Q4 2024.